Viridian Therapeutics, Inc.\DE (VRDN) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$35.1 million.
- Viridian Therapeutics, Inc.\DE's Income towards Parent Company rose 5417.68% to -$35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 1774.81%. This contributed to the annual value of -$269.9 million for FY2024, which is 1355.09% down from last year.
- As of Q3 2025, Viridian Therapeutics, Inc.\DE's Income towards Parent Company stood at -$35.1 million, which was up 5417.68% from -$100.7 million recorded in Q2 2025.
- Viridian Therapeutics, Inc.\DE's 5-year Income towards Parent Company high stood at -$14.0 million for Q3 2021, and its period low was -$100.7 million during Q2 2025.
- Its 5-year average for Income towards Parent Company is -$49.5 million, with a median of -$47.7 million in 2023.
- Examining YoY changes over the last 5 years, Viridian Therapeutics, Inc.\DE's Income towards Parent Company showed a top increase of 6811.34% in 2021 and a maximum decrease of 17773.65% in 2021.
- Viridian Therapeutics, Inc.\DE's Income towards Parent Company (Quarter) stood at -$28.9 million in 2021, then crashed by 58.17% to -$45.8 million in 2022, then tumbled by 46.03% to -$66.9 million in 2023, then decreased by 19.33% to -$79.8 million in 2024, then surged by 56.07% to -$35.1 million in 2025.
- Its last three reported values are -$35.1 million in Q3 2025, -$100.7 million for Q2 2025, and -$86.9 million during Q1 2025.